CureMatch
×
  • Physicians
  • BioPharma
  • Employers
  • News
  • Clinical Order
  • About Us
  • Login

A Patient’s Guide to Tumor Profiling

A Patient’s Guide to Tumor Profiling
Blog Posts

Every patient’s cancer is unique. However, the vast majority of cancer patients are still treated as if cancers can be grouped together by the organ of origin (e.g., colon cancer, breast cancer) rather than by looking at each cancer on an individual basis. Personalized medicine considers the uniqueness of each cancer patient’s tumor, and uses the description of mutated genes to define each patient’s unique set of therapeutic targets. In this approach, molecular profiling of the tumor, or tumor profiling, is the first step in the process.

The democratization of high throughput sequencing methods has allowed for the development of many companies offering tests that focus on different cancers and specific sets of genes. These include Foundation Medicine, Caris Life Science, Guardant Health, GenomeDx Biosciences, Intermountain Healthcare, Genomic Health, Trovagene, Varientyx, Invitae, Paradigm, and many others.

However, one size does not fit all, and evaluating the diverse set of molecular profiling tests can be a challenging and time-consuming task. When exploring molecular profiling options, many criteria should be taken into account, including biopsy type, tests offered, cancer type, profiling data type, turn-around time, and insurance coverage.

Biopsy Options:

The first step in the process is a biopsy, in which a sample of tissue, blood, or urine is taken from the patient’s body for analysis. It is important to consider the types of biopsy available, although for some cancer patients, the choice of biopsy maybe be limited to one option. For patients with hematological cancers and bone marrow cancers, a liquid biopsy may be the only viable choice. Conversely, if a patient has recently had surgery to remove some or all of their tumor, it may be best to request that a sample of the tumor be used for tumor profiling rather than performing a second procedure.

Recent studies found both similarities and differences between the results from solid and liquid biopsies to be similar. The pros and cons of different biopsy types are described below.

Solid biopsy

  • Requires removal of tissue from the tumor
  • Requires the tumor to be reachable and, its localization, clearly defined
  • Provides a sample of the mutations actually found within the tumor
  • Detects early-onset tumors for diagnosis and subtyping better than a blood biopsy
  • Can miss some mutations that are found in a limited section of the tumor
  • May not capture mutations in cancer cells that have spread to other parts of the body, unless the additional tumor locations are known

Liquid biopsy (blood and/or urine)

  • Analyzes the circulating cell free DNA (cfDNA) from cells that are shed into the bloodstream and urine by some tumors
  • Can capture mutations found in different tumor sites across the body
  • Can miss some mutations that are found in a limited section of a tumor
  • May not be able to capture mutations in cancer cells if the tumors are not releasing enough cells in the bloodstream

Guardant Health is one of the best-known tumor profiling companies that uses blood biopsies (Guardant360® test). But other DNA testing companies, such as Trovagene, utilize both blood and urine biopsies. Foundation Medicine offers profiling tests that can use either a solid biopsy or liquid biopsy. Most others use solid biopsies only.

Tests Offered & Cancer Types:

Tumor profiling companies use a variety of techniques to analyze the biopsy sample, and return information about the genes altered in the cancer cells. However, some companies only focus on specific cancer types. When selecting a tumor profiling company, it is important to know which types of cancer each company focuses on. Several examples are listed below:

CompanyTests Offered & Cancer Types
Caris Life SciencesCaris Molecular Intelligence: examines a large series of cancer genes for all cancer types. the biomarkers and technology platforms implemented may vary for each tumor type
Foundation MedicineFoundationOne: for solid tumors except pediatric tumors and sarcomas

FoundationOne Heme: for hematologic tumors, pediatric tumors, and sarcomas

Foundation ACT: for blood biopsies

 Guardant HealthGuardant360: all cancer types except hematological tumors
IntermountainICG100: examines a large series of cancer related genes for all cancer types
ParadigmPCDx: examines the most genomic variations for all solid tumor types
TrovageneTrovera: examines EGRF, KRAS, and BRAF genes for common solid tumors

Tumor Profiling Data Types:

Tumor profiling services use varying methods to analyze the patient’s tumor. For instance, some utilize next-generation DNA sequencing or RNA sequencing, while others analyze protein expression. The method used often depends on the biopsy type and nature of the cancer diagnosis. A patient should ask their oncologist about these different technology platforms.

Turn-Around Time: 

Most tests take an average of about 14 days, following receipt of the biopsy sample, but this can vary. In general, processing of liquid biopsies is faster than solid biopsies.

Insurance Coverage:

Costs for molecular profiling range from approximately $3,000 to $7,000; however, this range can vary significantly depending on the company or the number of genes being queried. Most insurance companies now cover molecular profiling tests, but the amount of coverage and the amount of the copay depends on a patient’s insurance provider and whether or not the patient has met the deductible. When a test is covered by insurance, the out-of-pocket cost is generally $500 or less.

If a test is not covered by insurance, the molecular profiling company may appeal to the insurance company on behalf of the patient, or if the claim is denied, the company may agree to significantly reduce the cost for the patient if they pay out-of-pocket. Pricing and insurance information is sometimes available through the company’s website, or may require further inquiry via phone or email.

-Nicole Mouchamel

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • Launch of CureMatch Certified Precision Oncology Recognition Award

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

  • The Complex Cancer Puzzle | Video 1

    ShareLinkedInFacebookTwitterRedditEmailPrint

  • CureMatch and Mprobe Partner to Help Cancer Patients Determine Optimal Treatments

    CureMatch will leverage mProbe’s targeted proteomics platform to assess individual proteins within patients’ tumor tissues....

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

Validation

  • Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

    Malignancies are molecularly complex and become more resistant with each line of...

  • Significance of Scores Generated by a Cancer Therapy Matching Engine for Patient Outcomes

    Oncologists need effective precision medicine tools to navigate the myriad of therapeutic...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

Archives

  • May 2024 (1)
  • October 2023 (1)
  • June 2023 (1)
  • May 2023 (1)
  • March 2023 (1)
  • January 2023 (1)
  • July 2022 (2)
  • June 2022 (2)
  • April 2022 (1)
  • March 2022 (1)
  • February 2022 (3)
  • November 2021 (1)
  • October 2021 (2)
  • August 2021 (2)
  • July 2021 (1)
  • June 2021 (4)
  • May 2021 (1)
  • April 2021 (2)
  • March 2021 (1)
  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • April 2019 (1)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 215-1313

Quick Links

  • Home
  • Physicians
  • About CureMatch
  • News and Latest Posts
  • Contact Us
  • FAQ

Latest News and Results

  • Launch of CureMatch Certified Precision Oncology Recognition Award May 8

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment Oct 7

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments Jun 28

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

© 2025 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

Please fill out the information below and a CureMatch representative will reach out to you.

 

Physician Request

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data